Effects of tirzepatide on body weight and cardiometabolic risk factors in people with overweight or obesity: a post hoc analysis of the SURPASS clinical trial program
Medical intelligence in Sweden
In addition, the Tac level appears to be relatively constant during the day and night when using continuous i.v
[1] Retatrutide (trials): once-weekly subcutaneous administration, starting low (e.g., 2 mg) and escalating to 4, 8, or 12 mg maintenance, with slower titration used to improve tolerability
CrossRef Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis Cong Liu, Milena Schnke, Enchen Zhou, Zhuang Li, Sander Kooijman, Maritte R Boon, Mikael Larsson, Kristina Wallenius, Niek Dekker, Louise Barlind, Xiao-Rong Peng, Yanan Wang, Patrick C N Rensen Cardiovascular Research.2022